Cargando…
Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma
PURPOSE: The objective of this study is to estimate radiotherapy (RT) modalities for patients with stage I-II nasal natural killer T-Cell lymphoma (NNKTCL), including plan quality, radiation delivery efficiency, cost of RT and excess absolute risk (EAR). MATERIALS AND METHODS: Twenty-four representa...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681560/ https://www.ncbi.nlm.nih.gov/pubmed/31534370 http://dx.doi.org/10.2147/CMAR.S201514 |
_version_ | 1783441747428245504 |
---|---|
author | Liu, Xianfeng Wu, Furong Guo, Qishuai Wang, Ying He, Yanan Luo, Huanli Li, Qicheng Zhong, Mingsong Li, Chao Yang, Han Zhou, Juan Jin, Fu |
author_facet | Liu, Xianfeng Wu, Furong Guo, Qishuai Wang, Ying He, Yanan Luo, Huanli Li, Qicheng Zhong, Mingsong Li, Chao Yang, Han Zhou, Juan Jin, Fu |
author_sort | Liu, Xianfeng |
collection | PubMed |
description | PURPOSE: The objective of this study is to estimate radiotherapy (RT) modalities for patients with stage I-II nasal natural killer T-Cell lymphoma (NNKTCL), including plan quality, radiation delivery efficiency, cost of RT and excess absolute risk (EAR). MATERIALS AND METHODS: Twenty-four representative patients with stage I-II NNKTCL treated with fix-field intensity-modulated radiotherapy (FF-IMRT) were re-planned for volumetric modulated arc therapy (VMAT), TomoDirect (TD) and TomoHelical (TH) on the TomoHDA system, respectively. Plan characteristics, cost of RT and EAR were compared. RESULTS: Compared with IMRT, TD and TH showed significant improvement in terms of D(98%), D(2%), cold spot volume and homogeneity index (HI) of planning target volume (PTV), while achieving worse D(mean) and conformity index (CI). The mean dose of oropharynx, thyroid and left salivary, and the maximum dose of right salivary by TD (249.20%, p=0.000; 52.94%, p=0.000; 160.23%, p=0.022; 122.67%, p=0.027), VMAT (15.76%, p=0.000; 23.53%, p=0.000; 34.09%, p=0.000; 31.33%, p=0.000) and TH (250.32%, p=0.000; 58.82%, p=0.000; 120.45%, p=0.020; 117.33%, p=0.032) increased significantly compared to IMRT. VMAT reduced treatment time (p=0.000; 0.000; 0.000) and monitor units (MUs) (p=0.000; 0.000; 0.000) obviously compared with IMRT, TD and TH. The cost of RT for TD and TH increased 150% compared with IMRT and VMAT. IMRT obtained the lowest EAR to oropharynx, thyroid, left and right salivary gland in the four treatment modalities. CONCLUSION: The results show that both TD and TH can achieve higher conformal target quality while getting worse organs at risk (OARs) sparing and EAR to some organs than IMRT for patients with stage I-II NNKTCL. IMRT delivers the lowest dose to most OARs, VMAT requires the lower cost of RT and shortest delivery time, and TH obtained the optimal target coverage. The results could provide direction for selecting proper RT modalities for different cases. |
format | Online Article Text |
id | pubmed-6681560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-66815602019-09-18 Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma Liu, Xianfeng Wu, Furong Guo, Qishuai Wang, Ying He, Yanan Luo, Huanli Li, Qicheng Zhong, Mingsong Li, Chao Yang, Han Zhou, Juan Jin, Fu Cancer Manag Res Original Research PURPOSE: The objective of this study is to estimate radiotherapy (RT) modalities for patients with stage I-II nasal natural killer T-Cell lymphoma (NNKTCL), including plan quality, radiation delivery efficiency, cost of RT and excess absolute risk (EAR). MATERIALS AND METHODS: Twenty-four representative patients with stage I-II NNKTCL treated with fix-field intensity-modulated radiotherapy (FF-IMRT) were re-planned for volumetric modulated arc therapy (VMAT), TomoDirect (TD) and TomoHelical (TH) on the TomoHDA system, respectively. Plan characteristics, cost of RT and EAR were compared. RESULTS: Compared with IMRT, TD and TH showed significant improvement in terms of D(98%), D(2%), cold spot volume and homogeneity index (HI) of planning target volume (PTV), while achieving worse D(mean) and conformity index (CI). The mean dose of oropharynx, thyroid and left salivary, and the maximum dose of right salivary by TD (249.20%, p=0.000; 52.94%, p=0.000; 160.23%, p=0.022; 122.67%, p=0.027), VMAT (15.76%, p=0.000; 23.53%, p=0.000; 34.09%, p=0.000; 31.33%, p=0.000) and TH (250.32%, p=0.000; 58.82%, p=0.000; 120.45%, p=0.020; 117.33%, p=0.032) increased significantly compared to IMRT. VMAT reduced treatment time (p=0.000; 0.000; 0.000) and monitor units (MUs) (p=0.000; 0.000; 0.000) obviously compared with IMRT, TD and TH. The cost of RT for TD and TH increased 150% compared with IMRT and VMAT. IMRT obtained the lowest EAR to oropharynx, thyroid, left and right salivary gland in the four treatment modalities. CONCLUSION: The results show that both TD and TH can achieve higher conformal target quality while getting worse organs at risk (OARs) sparing and EAR to some organs than IMRT for patients with stage I-II NNKTCL. IMRT delivers the lowest dose to most OARs, VMAT requires the lower cost of RT and shortest delivery time, and TH obtained the optimal target coverage. The results could provide direction for selecting proper RT modalities for different cases. Dove 2019-07-30 /pmc/articles/PMC6681560/ /pubmed/31534370 http://dx.doi.org/10.2147/CMAR.S201514 Text en © 2019 Liu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Liu, Xianfeng Wu, Furong Guo, Qishuai Wang, Ying He, Yanan Luo, Huanli Li, Qicheng Zhong, Mingsong Li, Chao Yang, Han Zhou, Juan Jin, Fu Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma |
title | Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma |
title_full | Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma |
title_fullStr | Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma |
title_full_unstemmed | Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma |
title_short | Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma |
title_sort | estimation of radiotherapy modalities for patients with stage i-ii nasal natural killer t-cell lymphoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681560/ https://www.ncbi.nlm.nih.gov/pubmed/31534370 http://dx.doi.org/10.2147/CMAR.S201514 |
work_keys_str_mv | AT liuxianfeng estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma AT wufurong estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma AT guoqishuai estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma AT wangying estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma AT heyanan estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma AT luohuanli estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma AT liqicheng estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma AT zhongmingsong estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma AT lichao estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma AT yanghan estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma AT zhoujuan estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma AT jinfu estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma |